Effects of simvastatin on walking performance and symptoms of intermittent claudication in hypercholesterolemic patients with peripheral vascular disease

Mondillo, Sergio; Ballo, Piercarlo; Barbati, Riccardo; Guerrini, Francesco; Ammaturo, T; Agricola, Eustachio; Pastore, M C; Borrello, F; Belcastro, Mirko; Picchi, Andrea; Nami, R

doi:10.1016/s0002-9343(03)00010-x

Cited by 247 publications

(158 citation statements)

References 26 publications

Supporting

Mentioning

148

Contrasting

Unclassified

Order By: Relevance

“…In a posthoc analysis of the Scandinavian Simvastatin Survival Study (4S) data (6), new or worsening of claudication was reduced in the group receiving simvastatin. Another study reported a similar beneficial effect of simvastatin on walking time in patients with PAD (7). Recently, Mohler et al (8) clearly showed that 12 months of atorvastatin therapy at a daily dose of 80 mg improved pain-free walking distance due to PAD in a study including 354 patients with claudication.…”

Section: Introductionmentioning

confidence: 81%

“…Increased stiffness of the arteries in the lower limbs is associated with impaired arterial blood flow (14,30), subclinical hypoxia of the foot (15), and ischemic symptoms of the lower extremities (16). Thus, the decreased PWV in the leg arteries following atorvastatin treatment may have beneficial effects on local blood flow, accounting for the favorable effects on walking performance (6)(7)(8).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Effect of Atorvastatin on Regional Arterial Stiffness in Patients with Type 2 Diabetes Mellitus

Shinohara

Shoji

Kimoto

et al. 2005

JAT

View full text Add to dashboard Cite

Objective: A statin, a potent lipid-lowering drug, improves pain-free walking distance in patients with peripheral arterial disease (PAD) without increasing the ankle-brachial pressure index (ABI). Arterial stiffness affects the blood flow of peripheral arteries. The purpose of this study was to evaluate the effect of cholesterol-lowering with atorvastatin on regional arterial stiffness in patients with type 2 diabetes mellitus. Methods: The subjects were 22 type 2 diabetic patients with hypercholesterolemia, who received atorvastatin at a daily dose of 10 mg for 6 months. Before and after the treatment with atorvastatin, we measured pulse wave velocity (PWV) in the heartbrachial, heart-carotid, heart-femoral and femoral-ankle segments. Results: Following treatment with atorvastatin, femoral-ankle PWV showed a significant reduction. The PWV of other arterial segments tended to decrease, although the changes were not statistically significant. We found no significant changes in blood pressure, heart rate, ABI, or plasma concentrations of glucose, L-arginine and asymmetric dimethylarginine (

show abstract

Section: Introductionmentioning

confidence: 81%

Section: Discussionmentioning

confidence: 99%

Effect of Atorvastatin on Regional Arterial Stiffness in Patients with Type 2 Diabetes Mellitus

Shinohara

Shoji

Kimoto

et al. 2005

JAT

View full text Add to dashboard Cite

show abstract

“…101 Mondillo 2003 did not report any clinical outcomes other than walking distances. 105 Many studies were also too small to show a statistically significant effect in relation to nonfatal outcomes. However, meta-analysis of data from all studies that provided such data in usable form indicates that statins are associated with a reduction in the risk of non-fatal stroke, TIA, nonfatal MI ( Figure 5), unstable angina and hospitalisations for unstable angina.…”

Section: Assessment Of Effectiveness Of Statins: All Placebo-controllmentioning

confidence: 99%

A systematic review and economic evaluation of statins for the prevention of coronary events

Ward

Jones²,

Pandor³

et al. 2007

Health Technol Assess

346

312

View full text Add to dashboard Cite

Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per monograph and for the rest of the world £3 per monograph.You can order HTA monographs from our Despatch Agents:-fax (with credit card or official purchase order) -post (with credit card or official purchase order or cheque) -phone during office hours (credit card only).Additionally the HTA website allows you either to pay securely by credit card or to print out your order and then post or fax it. NHS libraries can subscribe free of charge. Public libraries can subscribe at a very reduced cost of £100 for each volume (normally comprising 30-40 titles). The commercial subscription rate is £300 per volume. Please see our website for details. Subscriptions can only be purchased for the current or forthcoming volume. Contact details are as follows: Payment methods Paying by chequeIf you pay by cheque, the cheque must be in pounds sterling, made payable to Direct Mail Works Ltd and drawn on a bank with a UK address. Paying by credit cardThe following cards are accepted by phone, fax, post or via the website ordering pages: Delta, Eurocard, Mastercard, Solo, Switch and Visa. We advise against sending credit card details in a plain email. Paying by official purchase orderYou can post or fax these, but they must be from public bodies (i.e. NHS or universities) within the UK. We cannot at present accept purchase orders from commercial companies or from outside the UK. How do I get a copy of HTA on CD?Please use the form on the HTA website (www.hta.ac.uk/htacd.htm). Or contact Direct Mail Works (see contact details above) by email, post, fax or phone. HTA on CD is currently free of charge worldwide.The website also provides information about the HTA Programme and lists the membership of the various committees. HTA NIHR Health Technology Assessment ProgrammeT he Health Technology Assessment (HTA) Programme, now part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the costs, effectiveness and broader impact of health technologies for those who use, manage and provide care in the NHS. 'Health technologies' are broadly defined to include all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care, rather than settings of care. The research findings from the HTA Programme directly influence decision-making bodies such as the National Institute for Health and Clinical Excellence (NICE) and the National Screening Committee (NSC). HTA findings also help to improve the quality of clinical practice in the NHS indirectly in that they form a key component of the 'National Knowledge Service'. The HTA Programme is needs-led in that it fills gaps in the evidence needed by the NHS. There are three routes to the start of projects. First is the commissioned route. Suggestions for research are actively sought from people working in the NHS, the public and consumer groups and professional bodies such as r...

show abstract

“…81 Several studies have evaluated the role of statins on claudication symptoms and walking duration and have shown that these agents may have a modest effect at best. 82,83 The current recommendations advocate a goal LDL-C level of less than 100 mg/dL for patients with PAD; for very high-risk patients, the goal is an LDL-C level of less than 70 mg/dL. 4 Because all patients with PAD are at very high risk, lowering the LDL-C level to less than 70 mg/dL in all patients with PAD is reasonable.…”

mentioning

confidence: 99%

Peripheral Artery Disease: Current Insight Into the Disease and Its Diagnosis and Management

Olin

Sealove

2010

Mayo Clinic Proceedings

275

183

View full text Add to dashboard Cite

Effects of simvastatin on walking performance and symptoms of intermittent claudication in hypercholesterolemic patients with peripheral vascular disease

Cited by 247 publications

References 26 publications

Effect of Atorvastatin on Regional Arterial Stiffness in Patients with Type 2 Diabetes Mellitus

Effect of Atorvastatin on Regional Arterial Stiffness in Patients with Type 2 Diabetes Mellitus

A systematic review and economic evaluation of statins for the prevention of coronary events

Peripheral Artery Disease: Current Insight Into the Disease and Its Diagnosis and Management

Contact Info

Product

Resources

About